<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM" IndexingMethod="Curated"><PMID Version="1">39336433</PMID><DateCompleted><Year>2024</Year><Month>09</Month><Day>28</Day></DateCompleted><DateRevised><Year>2024</Year><Month>10</Month><Day>02</Day></DateRevised><Article PubModel="Electronic"><Journal><ISSN IssnType="Electronic">1648-9144</ISSN><JournalIssue CitedMedium="Internet"><Volume>60</Volume><Issue>9</Issue><PubDate><Year>2024</Year><Month>Aug</Month><Day>25</Day></PubDate></JournalIssue><Title>Medicina (Kaunas, Lithuania)</Title><ISOAbbreviation>Medicina (Kaunas)</ISOAbbreviation></Journal><ArticleTitle>Association of Human Leukocyte Antigen Alleles with COVID-19 Severity and Mortality in a Spanish Population.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">1392</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.3390/medicina60091392</ELocationID><Abstract><AbstractText><i>Background and Objectives</i>: The aim of the following cross-sectional study is to determine the association between human leukocyte antigen (HLA) alleles and outcomes in patients presenting to the emergency department (ED) with SARS-CoV-2 infection. <i>Methods and Materials</i>: Genotyping was made using the Axiom Human Genotyping SARS-CoV-2 Research Array. Statistical analysis was made with Fisher's exact test and multivariable logistic regression, adjusted for sex, age and clinical variables. <i>Results</i>: Of 190 patients, 11.1% were discharged from the ED; 57.9% were admitted to the COVID-19 ward, without intensive care unit (ICU) admission; 15.3% survived an ICU admission; and 15.8% died. After multivariable analysis, two HLA alleles protected against hospital admission (HLA-C*05:01, adjusted odds ratio [aOR] 0.2, 95% confidence interval [CI] 0.055-0.731; and HLA-DQB1*02:02, aOR 0.046, CI 0.002-0.871) and one was associated with higher risk for ICU admission or death (HLA-DQA1*05:01, aOR 2.517, CI 1.086-5.833). <i>Conclusions</i>: In this population, HLA-C*05:01 and HLA-DQB1*02:02 are associated with a protective effect against hospital admission and HLA-DQA1*05:01 is associated with higher risk of ICU admission or death in the multivariable analysis. This may help stratify risk in COVID-19 patients.</AbstractText></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Lobato-Martinez</LastName><ForeName>Ester</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0002-1138-2388</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Muriel-Serrano</LastName><ForeName>Javier</ForeName><Initials>J</Initials><Identifier Source="ORCID">0000-0003-0048-9451</Identifier><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>García-Payá</LastName><ForeName>Elena</ForeName><Initials>E</Initials><Identifier Source="ORCID">0000-0003-0032-0197</Identifier><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Analysis Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Gonzalez-de-la-Aleja</LastName><ForeName>Pilar</ForeName><Initials>P</Initials><Identifier Source="ORCID">0000-0001-9360-7394</Identifier><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Infectious Diseases Unit, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Garcia-Sevila</LastName><ForeName>Raquel</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0002-4218-793X</Identifier><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Pneumology Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Navarro-de-Miguel</LastName><ForeName>Mercedes</ForeName><Initials>M</Initials><Identifier Source="ORCID">0000-0003-3792-7363</Identifier><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Analysis Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Marco-de-la-Calle</LastName><ForeName>Francisco</ForeName><Initials>F</Initials><Identifier Source="ORCID">0000-0001-5113-3637</Identifier><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Immunology Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramos-Rincon</LastName><ForeName>Jose-Manuel</ForeName><Initials>JM</Initials><Identifier Source="ORCID">0000-0001-7922-5664</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Miguel Hernández University, N-332, 87, 03550 Alicante, Spain.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez-Martinez</LastName><ForeName>Rosario</ForeName><Initials>R</Initials><Identifier Source="ORCID">0000-0003-3825-0198</Identifier><AffiliationInfo><Affiliation>Internal Medicine Department, Dr. Balmis Universitary General Hospital, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Alicante Institute for Health and Biomedical Research (ISABIAL), Centro de Diagnóstico, Edif Gris, Planta 5ª, Avenida Pintor Baeza, 12, 03010 Alicante, Spain.</Affiliation></AffiliationInfo><AffiliationInfo><Affiliation>Clinical Medicine Department, Miguel Hernández University, N-332, 87, 03550 Alicante, Spain.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>Call for Research Grants 2020</GrantID><Agency>Sociedad de Medicina Interna de la Comunidad Valenciana</Agency><Country /></Grant><Grant><GrantID>Ref: 2020-0337</GrantID><Agency>Institute for Health and Biomedical Research of Alicante (ISABIAL)</Agency><Country /></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>25</Day></ArticleDate></Article><MedlineJournalInfo><Country>Switzerland</Country><MedlineTA>Medicina (Kaunas)</MedlineTA><NlmUniqueID>9425208</NlmUniqueID><ISSNLinking>1010-660X</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D006680">HLA Antigens</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059848">HLA-DQ alpha-Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C069050">HLA-DQA1 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C069051">HLA-DQB1 antigen</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D059866">HLA-DQ beta-Chains</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015236">HLA-C Antigens</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><MeshHeadingList><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086382" MajorTopicYN="Y">COVID-19</DescriptorName><QualifierName UI="Q000401" MajorTopicYN="N">mortality</QualifierName><QualifierName UI="Q000276" MajorTopicYN="N">immunology</QualifierName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D013030" MajorTopicYN="N" Type="Geographic">Spain</DescriptorName><QualifierName UI="Q000453" MajorTopicYN="N">epidemiology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D003430" MajorTopicYN="N">Cross-Sectional Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000483" MajorTopicYN="Y">Alleles</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000086402" MajorTopicYN="N">SARS-CoV-2</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D012720" MajorTopicYN="N">Severity of Illness Index</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006680" MajorTopicYN="N">HLA Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059848" MajorTopicYN="N">HLA-DQ alpha-Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D059866" MajorTopicYN="N">HLA-DQ beta-Chains</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D015236" MajorTopicYN="N">HLA-C Antigens</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="N">genetics</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D007362" MajorTopicYN="N">Intensive Care Units</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D004636" MajorTopicYN="N">Emergency Service, Hospital</DescriptorName><QualifierName UI="Q000706" MajorTopicYN="N">statistics &amp; numerical data</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D005838" MajorTopicYN="N">Genotype</DescriptorName></MeshHeading></MeshHeadingList><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19</Keyword><Keyword MajorTopicYN="N">HLA antigens</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">genetic</Keyword><Keyword MajorTopicYN="N">genetic predisposition to disease</Keyword><Keyword MajorTopicYN="N">hospitalization</Keyword><Keyword MajorTopicYN="N">mortality</Keyword><Keyword MajorTopicYN="N">polymorphism</Keyword></KeywordList><CoiStatement>The authors declare no conflicts of interest. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>7</Month><Day>4</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>8</Month><Day>12</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>9</Month><Day>29</Day><Hour>1</Hour><Minute>18</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>22</Hour><Minute>43</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>9</Month><Day>28</Day><Hour>1</Hour><Minute>11</Minute></PubMedPubDate><PubMedPubDate PubStatus="pmc-release"><Year>2024</Year><Month>8</Month><Day>25</Day></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39336433</ArticleId><ArticleId IdType="pmc">PMC11434301</ArticleId><ArticleId IdType="doi">10.3390/medicina60091392</ArticleId><ArticleId IdType="pii">medicina60091392</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Amoroso A., Magistroni P., Vespasiano F., Bella A., Bellino S., Puoti F., Alizzi S., Vaisitti T., Boros S., Grossi P.A., et al. HLA and AB0 Polymorphisms May Influence SARS-CoV-2 Infection and COVID-19 Severity. Transplantation. 2021;105:193–200. doi: 10.1097/TP.0000000000003507.</Citation><ArticleIdList><ArticleId IdType="doi">10.1097/TP.0000000000003507</ArticleId><ArticleId IdType="pubmed">33141807</ArticleId></ArticleIdList></Reference><Reference><Citation>Pojero F., Candore G., Caruso C., Di Bona D., Groneberg D.A., Ligotti M.E., Accardi G., Aiello A. The Role of Immunogenetics in COVID-19. Int. J. Mol. Sci. 2021;22:2636. doi: 10.3390/ijms22052636.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/ijms22052636</ArticleId><ArticleId IdType="pmc">PMC7961811</ArticleId><ArticleId IdType="pubmed">33807915</ArticleId></ArticleIdList></Reference><Reference><Citation>Deb P., Zannat K., Talukder S., Bhuiyan A.H., Jilani S.A., Saif-Ur-Rahman K.M. Association of HLA gene polymorphism with susceptibility, severity, and mortality of COVID-19: A systematic review. HLA. 2022;99:281–312. doi: 10.1111/tan.14560.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/tan.14560</ArticleId><ArticleId IdType="pubmed">35067002</ArticleId></ArticleIdList></Reference><Reference><Citation>Littera R., Campagna M., Deidda S., Angioni G., Cipri S., Melis M. Human Leukocyte Antigen Complex and Other Immunogenetic and Clinical Factors Influence Susceptibility or Protection to SARS-CoV-2 Infection and Severity of the Disease Course. The Sardinian Experience. Front. Immunol. 2020;11:605688. doi: 10.3389/fimmu.2020.605688.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2020.605688</ArticleId><ArticleId IdType="pmc">PMC7746644</ArticleId><ArticleId IdType="pubmed">33343579</ArticleId></ArticleIdList></Reference><Reference><Citation>Instituto de Salud Carlos III  Informe nº 181: Situación de COVID-19 en España. 2023.  [(accessed on 10 January 2024)].  Available online:  https://www.isciii.es/QueHacemos/Servicios/VigilanciaSaludPublicaRENAVE/EnfermedadesTransmisibles/Documents/INFORMES/Informes%20COVID-19/INFORMES%20COVID-19%202023/Informe%20n%C2%BA%20181%20Situaci%C3%B3n%20actual%20de%20COVID-19%20en%20Espa%C3%B1a%20a%2030%20de%20junio%20de%202023.pdf.</Citation></Reference><Reference><Citation>Dieter C., de Almeida Brondani L., Bauermann Leitão C., Gerchman F., Emerim Lemos N., Crispim D. Genetic polymorphisms associated with susceptibility to COVID-19 disease and severity: A systematic review and metaanalysis. PLoS ONE. 2022;17:e0270627. doi: 10.1371/journal.pone.0270627.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0270627</ArticleId><ArticleId IdType="pmc">PMC9258831</ArticleId><ArticleId IdType="pubmed">35793369</ArticleId></ArticleIdList></Reference><Reference><Citation>Lorente L., Martín M.M., Franco A., Barrio Y., Cáceres J.J., Solé-Violán J., Perez A., Marcos y Ramos J.A., Ramos-Gómez L., Ojeda N., et al. HLA genetic polymorphisms and prognosis of patients with COVID-19. Med. Intensiv. 2021;45:96–103. doi: 10.1016/j.medin.2020.08.004.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.medin.2020.08.004</ArticleId><ArticleId IdType="pmc">PMC7474921</ArticleId><ArticleId IdType="pubmed">38620408</ArticleId></ArticleIdList></Reference><Reference><Citation>Gutiérrez-Bautista J.F., Rodriguez-Nicolas A., Rosales-Castillo A., López-Ruiz M.A., Martín-Casares A.M., Fernández-Rubiales A., Anderson P., Garrido F., Ruiz-Cabello F., López-Nevot M.A. Study of HLA-A, -B, -C, -DRB1 and -DQB1 polymorphisms in COVID-19 patients. J. Microbiol. Immunol. Infect. 2022;55:421–427. doi: 10.1016/j.jmii.2021.08.009.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.jmii.2021.08.009</ArticleId><ArticleId IdType="pmc">PMC8384756</ArticleId><ArticleId IdType="pubmed">34475005</ArticleId></ArticleIdList></Reference><Reference><Citation>Severe Covid-19 GWAS Group Genomewide Association Study of Severe COVID-19 with Respiratory Failure. N. Engl. J. Med. 2020;383:1522–1534. doi: 10.1056/NEJMoa2020283.</Citation><ArticleIdList><ArticleId IdType="doi">10.1056/NEJMoa2020283</ArticleId><ArticleId IdType="pmc">PMC7315890</ArticleId><ArticleId IdType="pubmed">32558485</ArticleId></ArticleIdList></Reference><Reference><Citation>Weiner J., Suwalski P., Holtgrewe M., Rakitko A., Thibeault C., Müller M., Patriki D., Quedenau C., Krüger U., Ilinsky V., et al. Increased risk of severe clinical course of COVID-19 in carriers of HLA-C*04:01. EClinicalMedicine. 2021;40:101099. doi: 10.1016/j.eclinm.2021.101099.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.eclinm.2021.101099</ArticleId><ArticleId IdType="pmc">PMC8410317</ArticleId><ArticleId IdType="pubmed">34490415</ArticleId></ArticleIdList></Reference><Reference><Citation>Tomita Y., Ikeda T., Sato R., Sakagami T. Association between HLA gene polymorphisms and mortality of COVID-19: An in silico analysis. Immun. Inflamm. Dis. 2020;8:684–694. doi: 10.1002/iid3.358.</Citation><ArticleIdList><ArticleId IdType="doi">10.1002/iid3.358</ArticleId><ArticleId IdType="pmc">PMC7654404</ArticleId><ArticleId IdType="pubmed">33047883</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishii T. Human Leukocyte Antigen (HLA) Class I Susceptible Alleles Against COVID-19 Increase Both Infection and Severity Rate. Cureus. 2020;12:e12239. doi: 10.7759/cureus.12239.</Citation><ArticleIdList><ArticleId IdType="doi">10.7759/cureus.12239</ArticleId><ArticleId IdType="pmc">PMC7773525</ArticleId><ArticleId IdType="pubmed">33403186</ArticleId></ArticleIdList></Reference><Reference><Citation>Verlouw J.A.M., Clemens E., de Vries J.H., Zolk O., Verkerk A.J.M.H., Am Zehnhoff-Dinnesen A., Medina-Gomez C., Lanvers-Kaminsy C., Rivadeneira F., Langer T., et al. A comparison of genotyping arrays. Eur. J. Hum. Genet. 2021;29:1611–1624. doi: 10.1038/s41431-021-00917-7.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s41431-021-00917-7</ArticleId><ArticleId IdType="pmc">PMC8560858</ArticleId><ArticleId IdType="pubmed">34140649</ArticleId></ArticleIdList></Reference><Reference><Citation>Dilthey A., Leslie S., Moutsianas L., Shen J., Cox C., Nelson M.R., McVean G. Multi-Population Classical HLA Type Imputation. PLoS Comput. Biol. 2013;9:e1002877. doi: 10.1371/journal.pcbi.1002877.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pcbi.1002877</ArticleId><ArticleId IdType="pmc">PMC3572961</ArticleId><ArticleId IdType="pubmed">23459081</ArticleId></ArticleIdList></Reference><Reference><Citation>Karnes J.H., Shaffer C.M., Bastarache L., Gaudieri S., Glazer A.M., Steiner H.E., Mosley J.D., Mallal S., Denny J.C., Phillips E.J., et al. Comparison of HLA allelic imputation programs. PLoS ONE. 2017;12:e0172444. doi: 10.1371/journal.pone.0172444.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0172444</ArticleId><ArticleId IdType="pmc">PMC5312875</ArticleId><ArticleId IdType="pubmed">28207879</ArticleId></ArticleIdList></Reference><Reference><Citation>Gayán J., Galan J.J., González-Pérez A., Sáez M.E., Martínez-Larrad M.T., Zabena C., Rivero M.C., Salinas A., Ramírez-Lorca R., Morón F.J., et al. Genetic Structure of the Spanish Population. BMC Genom. 2010;11:326. doi: 10.1186/1471-2164-11-326.</Citation><ArticleIdList><ArticleId IdType="doi">10.1186/1471-2164-11-326</ArticleId><ArticleId IdType="pmc">PMC2887418</ArticleId><ArticleId IdType="pubmed">20500880</ArticleId></ArticleIdList></Reference><Reference><Citation>AxiomTM Analysis Suite (AxAS) Thermo Fisher Scientific Inc.; Waltham, MA, USA: 2022. v5.1.</Citation></Reference><Reference><Citation>Shen Y., Khatril B., Rananaware S., Li D., Ostrov D.A., Jain P.K., Lessard C.J., Nguyen C.Q. Ancestral origins are associated with SARSCoV-2 susceptibility and protection in a Florida patient population. PLoS ONE. 2023;18:e0276700. doi: 10.1371/journal.pone.0276700.</Citation><ArticleIdList><ArticleId IdType="doi">10.1371/journal.pone.0276700</ArticleId><ArticleId IdType="pmc">PMC9844918</ArticleId><ArticleId IdType="pubmed">36649279</ArticleId></ArticleIdList></Reference><Reference><Citation>Breno M., Noris M., Rubis N., Parvanova A.I., Martinetti D., Gamba S., Liguori L., Mele C., Piras R., Orisio S., et al. A GWAS in the pandemic epicenter highlights the severe COVID-19 risk locus introgressed by Neanderthals. iScience. 2023;26:107629. doi: 10.1016/j.isci.2023.107629.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.isci.2023.107629</ArticleId><ArticleId IdType="pmc">PMC10507134</ArticleId><ArticleId IdType="pubmed">37731612</ArticleId></ArticleIdList></Reference><Reference><Citation>Chamnanphon M., Pongpanich M., Suttichet T.B., Jantarabenjakul W., Torvorapanit P., Putcharoen O., Sodsai P., Phokaew C., Hirankarn N., Chariyavilaskul P., et al. Host genetic factors of COVID-19 susceptibility and disease severity in a Thai population. J. Hum. Genet. 2022;67:295–301. doi: 10.1038/s10038-021-01009-6.</Citation><ArticleIdList><ArticleId IdType="doi">10.1038/s10038-021-01009-6</ArticleId><ArticleId IdType="pmc">PMC8748005</ArticleId><ArticleId IdType="pubmed">35013560</ArticleId></ArticleIdList></Reference><Reference><Citation>Gonzalez-Galarza F.F., McCabe A., Santos E.J., Jones J., Takeshita L.Y., Ortega-Rivera N.D., Del Cid-Pavon G.M., Ramsbottom K., Ghattaoraya G., Alfirevic A., et al. Allele frequency net database (AFND) 2020 update: Gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020;8:D783–D788. doi: 10.1093/nar/gkz1029.</Citation><ArticleIdList><ArticleId IdType="doi">10.1093/nar/gkz1029</ArticleId><ArticleId IdType="pmc">PMC7145554</ArticleId><ArticleId IdType="pubmed">31722398</ArticleId></ArticleIdList></Reference><Reference><Citation>Poulton K., Wright P., Hughes P., Savic S., Welberry Smith M., Guiver M., Morton M., van Dellen D., Tholouli E., Wynn R., et al. A role for human leucocyte antigens in the susceptibility to SARS-Cov-2 infection observed in transplant patients. Int. J. Immunogenet. 2020;47:324–328. doi: 10.1111/iji.12505.</Citation><ArticleIdList><ArticleId IdType="doi">10.1111/iji.12505</ArticleId><ArticleId IdType="pmc">PMC7361549</ArticleId><ArticleId IdType="pubmed">32623831</ArticleId></ArticleIdList></Reference><Reference><Citation>Sakuraba A., Haider H., Sato T. Population Difference in Allele Frequency of HLA-C*05 and Its Correlation with COVID-19 Mortality. Viruses. 2020;12:1333. doi: 10.3390/v12111333.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/v12111333</ArticleId><ArticleId IdType="pmc">PMC7699862</ArticleId><ArticleId IdType="pubmed">33233780</ArticleId></ArticleIdList></Reference><Reference><Citation>Fricke-Galindo I., Falfán-Valencia R. Genetics Insight for COVID-19 Susceptibility and Severity: A Review. Front. Immunol. 2021;12:622176. doi: 10.3389/fimmu.2021.622176.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2021.622176</ArticleId><ArticleId IdType="pmc">PMC8047200</ArticleId><ArticleId IdType="pubmed">33868239</ArticleId></ArticleIdList></Reference><Reference><Citation>Lerner A., Benzvi C., Vojdani E. HLA-DQ2/8 and COVID-19 in Celiac Disease: Boon or Bane. Microorganisms. 2023;11:2977. doi: 10.3390/microorganisms11122977.</Citation><ArticleIdList><ArticleId IdType="doi">10.3390/microorganisms11122977</ArticleId><ArticleId IdType="pmc">PMC10745744</ArticleId><ArticleId IdType="pubmed">38138121</ArticleId></ArticleIdList></Reference><Reference><Citation>Koutsakos M., McWilliam H.E.G., Aktepe T.E., Fritzlar S., Illing P., Mifsud N.A., Purcell A.W., Rockman S., Reading P.C., Vivian J.P., et al. Downregulation of MHC Class I Expression by Influenza A and B Viruses. Front. Immunol. 2019;10:1158. doi: 10.3389/fimmu.2019.01158.</Citation><ArticleIdList><ArticleId IdType="doi">10.3389/fimmu.2019.01158</ArticleId><ArticleId IdType="pmc">PMC6548845</ArticleId><ArticleId IdType="pubmed">31191533</ArticleId></ArticleIdList></Reference><Reference><Citation>Bonagura V.R., Vambutas A., DeVoti J.A., Rosenthal D.W., Steinberg B.M., Abramson A.L., Shikowitz M.J., Gjertson D.W., Reed E.F. HLA Alleles, IFN-γ Responses to HPV-11 E6, and Disease Severity in Patients with Recurrent Respiratory Papillomatosis. Hum. Immunol. 2004;65:773–782. doi: 10.1016/j.humimm.2004.05.014.</Citation><ArticleIdList><ArticleId IdType="doi">10.1016/j.humimm.2004.05.014</ArticleId><ArticleId IdType="pubmed">15336778</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle>